Show simple item record

dc.contributor.authorMcFarlane, V
dc.contributor.authorFriedmann, P S
dc.contributor.authorIllidge, Timothy M
dc.date.accessioned2009-08-04T17:25:18Z
dc.date.available2009-08-04T17:25:18Z
dc.date.issued2005-05
dc.identifier.citationWhat's new in the management of cutaneous T-cell lymphoma? 2005, 17 (3):174-84 Clin Oncolen
dc.identifier.issn0936-6555
dc.identifier.pmid15901002
dc.identifier.urihttp://hdl.handle.net/10541/76282
dc.description.abstractThe aetiology and clinical management of primary cutaneous T-cell lymphoma (CTCL) and specifically of mycosis fungoides and Sezary syndrome are poorly defined. Interesting new insights into CTCL disease biology as well as a number of emerging of novel therapeutic interventions make this an increasingly interesting area for dermatologists and oncologists involved in the treatment of CTCL. This review article covers much of this new information including new drugs, such as denileukin diftitox (Ontak) a targeted cytotoxic biological agent, Bexarotene an RXR selective retinoid, anti-CD4 monoclonal antibodies (mAb), new cytotoxics agents and vaccines.
dc.language.isoenen
dc.subject.meshHumans
dc.subject.meshLymphoma, T-Cell, Cutaneous
dc.subject.meshMycosis Fungoides
dc.subject.meshPrognosis
dc.titleWhat's new in the management of cutaneous T-cell lymphoma?en
dc.typeArticleen
dc.contributor.departmentSouthampton Oncology Centre, Southampton University NHS Trust, Southampton S016 6YD, UK.en
dc.identifier.journalClinical Oncologyen
html.description.abstractThe aetiology and clinical management of primary cutaneous T-cell lymphoma (CTCL) and specifically of mycosis fungoides and Sezary syndrome are poorly defined. Interesting new insights into CTCL disease biology as well as a number of emerging of novel therapeutic interventions make this an increasingly interesting area for dermatologists and oncologists involved in the treatment of CTCL. This review article covers much of this new information including new drugs, such as denileukin diftitox (Ontak) a targeted cytotoxic biological agent, Bexarotene an RXR selective retinoid, anti-CD4 monoclonal antibodies (mAb), new cytotoxics agents and vaccines.


This item appears in the following Collection(s)

Show simple item record